Benjamin F. Edwards & Company’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $87K | Sell |
356
-48
| -12% | -$11.7K | ﹤0.01% | 1145 |
|
|
2024
Q1 | $60K | Buy |
404
+33
| +9% | +$4.9K | ﹤0.01% | 1241 |
|
|
2023
Q4 | $71K | Buy |
+371
| New | +$71K | ﹤0.01% | 1168 |
|
|
2023
Q1 | – | Sell |
-1,321
| Closed | -$314K | – | 1775 |
|
|
2022
Q4 | $314K | Buy |
+1,321
| New | +$314K | 0.01% | 590 |
|
|
2022
Q3 | – | Sell |
-28
| Closed | -$4K | – | 1813 |
|
|
2022
Q2 | $4K | Hold |
28
| – | – | ﹤0.01% | 1563 |
|
|
2022
Q1 | $5K | Hold |
28
| – | – | ﹤0.01% | 1499 |
|
|
2021
Q4 | $5K | Buy |
28
+11
| +65% | +$1.96K | ﹤0.01% | 1503 |
|
|
2021
Q3 | $3K | Buy |
17
+2
| +13% | +$353 | ﹤0.01% | 1582 |
|
|
2021
Q2 | $3K | Buy |
+15
| New | +$3K | ﹤0.01% | 1571 |
|
|
2018
Q4 | – | Sell |
-32
| Closed | -$3K | – | 1673 |
|
|
2018
Q3 | $3K | Sell |
32
-10
| -24% | -$938 | ﹤0.01% | 1453 |
|
|
2018
Q2 | $4K | Buy |
42
+15
| +56% | +$1.43K | ﹤0.01% | 1432 |
|
|
2018
Q1 | $3K | Hold |
27
| – | – | ﹤0.01% | 1460 |
|
|
2017
Q4 | $3K | Hold |
27
| – | – | ﹤0.01% | 1392 |
|
|
2017
Q3 | $3K | Hold |
27
| – | – | ﹤0.01% | 1345 |
|
|
2017
Q2 | $2K | Hold |
27
| – | – | ﹤0.01% | 1342 |
|
|
2017
Q1 | $1K | Hold |
27
| – | – | ﹤0.01% | 1287 |
|
|
2016
Q4 | $1K | Buy |
+27
| New | +$1K | ﹤0.01% | 1192 |
|